The established GLP-1 agonist vs the emerging triple-agonist for metabolic outcomes. Here's a neutral, sourced side-by-side — no hype, every claim links to its evidence.
Also: Ozempic, Rybelsus
Semaglutide is a special medicine that acts like a natural hormone in the body to help control blood sugar and weight. Studies show it can also help the heart and liver work better.While semaglutide helps many people, it does not work for every health issue.
Also: LY3437943
Unapproved and investigational peptides, including popular weight-loss drugs like retatrutide, semaglutide, and tirzepatide, alongside recovery compounds like BPC-157 and TB-500, are entering the U. S.
| Semaglutide | Retatrutide | |
|---|---|---|
| Research status | Approved | Preclinical |
| Benefits documented | 1504 | 450 |
| Research citations | 533 | 91 |
| Dosing routes | Subcutaneous | Subcutaneous |
| Known side effects | 764 | 155 |
Top documented benefits — backed by research.
Reported protocols — research only, not medical advice.
Key studies — click through to verify each on PubMed.
533 sourced studies
91 sourced studies
Retatrutide’s mechanisms of action
The First Triple Agonist for Antiobesity: Retatrutide
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Neither is a “winner” — they suit different goals. Compare the documented benefits and evidence above against what you’re actually trying to achieve, note the research status (approved vs research-stage), and read each full guide before deciding. Many people also stack peptides rather than pick one.
Source Semaglutide
Source Retatrutide